Literature DB >> 17143482

Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma.

So-Yeon Park1, Seoung-Ae Lee, In-Hee Han, Byong-Chul Yoo, Seung-Hoon Lee, Jo-Yong Park, In-Ho Cha, Jin Kim, Sung-Weon Choi.   

Abstract

The multifunctional G-protein-coupled metabotropic glutamate receptor (mGluR) family comprises eight subtypes, some of which participate in tumorigenesis. The purpose of this study was to evaluate mGluR5 expression in oral squamous cell carcinoma (SCC) tissues and oral cancer cell lines. We also investigated the prognostic significance of mGluR5 and its functional importance in the migration, invasion, and adhesion of oral cancer cells. We evaluated the expression of mGluR5 in samples from 131 oral SCC patients and in several oral cancer cell lines by immunohistochemistry and RT-PCR. We observed varying levels of mGluR5 in human oral SCC tissues and cancer cell lines. There was a significant association between strong mGluR5 immunoreactivity and overall survival (P=0.0109). The functional significance of the expression of mGluR5 in oral cancer cells was then investigated in HSC3 oral tongue cancer cells. An mGluR5 agonist, DHPG increased tumor cell migration, invasion, and adhesion in HSC3 cells (P<0.05). This was reversed by the mGluR5 antagonist MPEP. Our results strongly suggest that mGluR5 is a new prognostic marker and contributes to tumor cell migration and invasion in oral cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17143482

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  28 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

4.  Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.

Authors:  Branden A Smeester; Mary M Lunzer; Eyup Akgün; Alvin J Beitz; Philip S Portoghese
Journal:  Eur J Pharmacol       Date:  2014-09-17       Impact factor: 4.432

5.  High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Authors:  Wu Yang; He Maolin; Zhao Jinmin; Wang Zhe
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-08       Impact factor: 4.553

Review 6.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

Review 7.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

8.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

9.  Novel mGluR- and CB1R-independent suppression of GABA release caused by a contaminant of the group I metabotropic glutamate receptor agonist, DHPG.

Authors:  Carlos A Lafourcade; Longhua Zhang; Bradley E Alger
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

10.  Molecular profiling to identify molecular mechanism in esophageal cancer with familial clustering.

Authors:  Indranil Chattopadhyay; Rupkumar Phukan; Avninder Singh; Madavan Vasudevan; Joydeep Purkayastha; Stephen Hewitt; Amal Kataki; Jagadish Mahanta; Sujala Kapur; Sunita Saxena
Journal:  Oncol Rep       Date:  2009-05       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.